Know More About This Test

The Double Marker Test is a prenatal screening test performed in the first trimester (11–14 weeks) of pregnancy. It measures two biochemical markers—free β-hCG and PAPP-A—to assess the risk of chromosomal abnormalities such as Down syndrome (Trisomy 21) and Trisomy 18.

This test is often combined with nuchal translucency (NT) ultrasound for greater accuracy.

Why Is This Test Recommended?

• Early prenatal risk assessment

• Screen for chromosomal abnormalities

• Guide need for advanced diagnostic testing

• Reassure low-risk pregnancies

Understanding the Double Marker Test

Abnormal marker levels do not confirm a disorder but indicate increased risk, prompting further diagnostic tests like NIPT or amniocentesis.

Who Should Take This Test?

• All pregnant women

• Women above 30–35 years

• High-risk pregnancies

Preparation

• No fasting required

• Accurate gestational age essential

Results Interpretation

• Low risk: No further testing needed

• High risk: Diagnostic tests advised

FAQs

• Is it mandatory? No, the Double Marker Test is recommended but optional, particularly for women over 35 or those with risk factors, as it provides valuable early insights without being required for all pregnancies.

• Is it diagnostic? No, it is a screening test only and does not diagnose chromosomal abnormalities definitively; it calculates risk levels based on marker measurements, with high-risk results leading to confirmatory tests like amniocentesis.

• Can it harm the fetus? No, the Double Marker Test is completely safe and non-invasive, involving only a simple blood draw from the mother with no risk to the fetus or pregnancy.

• What if results are high risk? If results indicate high risk, further diagnostic tests such as non-invasive prenatal testing (NIPT), chorionic villus sampling (CVS), or amniocentesis are advised to confirm the findings and discuss options with a genetic counselor.

• Is ultrasound required? Yes, ultrasound is required for optimal accuracy, as it measures nuchal translucency alongside the blood markers to provide a combined risk assessment that's more reliable than blood tests alone.